MX2022004287A - Composiciones y métodos para tratar trastornos sanguineos. - Google Patents

Composiciones y métodos para tratar trastornos sanguineos.

Info

Publication number
MX2022004287A
MX2022004287A MX2022004287A MX2022004287A MX2022004287A MX 2022004287 A MX2022004287 A MX 2022004287A MX 2022004287 A MX2022004287 A MX 2022004287A MX 2022004287 A MX2022004287 A MX 2022004287A MX 2022004287 A MX2022004287 A MX 2022004287A
Authority
MX
Mexico
Prior art keywords
hemolytic anemia
thrombocytopenia
syndrome
antibody
warm
Prior art date
Application number
MX2022004287A
Other languages
English (en)
Spanish (es)
Inventor
Ted Yednock
Sethu Sankaranarayanan
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2022004287A publication Critical patent/MX2022004287A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2022004287A 2019-10-17 2020-10-16 Composiciones y métodos para tratar trastornos sanguineos. MX2022004287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Publications (1)

Publication Number Publication Date
MX2022004287A true MX2022004287A (es) 2022-07-19

Family

ID=75538375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004287A MX2022004287A (es) 2019-10-17 2020-10-16 Composiciones y métodos para tratar trastornos sanguineos.

Country Status (11)

Country Link
US (1) US20240109957A1 (enExample)
EP (1) EP4045084A4 (enExample)
JP (2) JP7809056B2 (enExample)
KR (1) KR20220083737A (enExample)
CN (1) CN114746118A (enExample)
AU (1) AU2020365132A1 (enExample)
BR (1) BR112022007051A2 (enExample)
CA (1) CA3157873A1 (enExample)
IL (1) IL292186A (enExample)
MX (1) MX2022004287A (enExample)
WO (1) WO2021076991A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
AU2021361067A1 (en) * 2020-10-16 2023-06-01 Annexon, Inc. Compositions and methods for treating blood disorders
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
CN106349390B (zh) * 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
PT2861246T (pt) * 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
SG11201510316UA (en) * 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
PL3215527T3 (pl) * 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä

Also Published As

Publication number Publication date
CA3157873A1 (en) 2021-04-22
JP2022551751A (ja) 2022-12-13
AU2020365132A1 (en) 2022-04-28
EP4045084A4 (en) 2023-05-31
KR20220083737A (ko) 2022-06-20
EP4045084A1 (en) 2022-08-24
WO2021076991A1 (en) 2021-04-22
US20240109957A1 (en) 2024-04-04
JP2026028257A (ja) 2026-02-19
JP7809056B2 (ja) 2026-01-30
CN114746118A (zh) 2022-07-12
IL292186A (en) 2022-06-01
BR112022007051A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
BR112022007051A2 (pt) Composições e métodos para tratamento de distúrbios hematológicos
Holodick et al. Defining natural antibodies
Klimatcheva et al. CXCL13 antibody for the treatment of autoimmune disorders
Tiller et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody‐mediated immune suppression and prevention of severe clinical complications in a murine model
BR112019001806A2 (pt) anticorpos para fcrn e métodos de uso dos mesmos
Nguyen et al. Natural IgM and the development of B cell-mediated autoimmune diseases
Dempsey et al. Mortality in Joubert syndrome
Brodersen Bovine viral diarrhea virus infections: manifestations of infection and recent advances in understanding pathogenesis and control
Agarwal et al. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
Han et al. Immune modulation of iv immunoglobulin in women with reproductive failure
MX2023004429A (es) Composiciones y metodos para tratar trastornos sanguineos.
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
Lichtenthäler et al. Goal-Predictability vs. Trajectory-Predictability–Which Legibility Factor Counts
Fenutría et al. Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses
Kjeldsen-Kragh et al. Mechanisms and prevention of alloimmunization in pregnancy
Turgutkaya et al. COVID-19-associated Evans syndrome: A case report and review of the literature
Ehounoud et al. Bacterial arthropod-borne diseases in West Africa
Cruz-Leal et al. Prevention of hemolytic disease of the fetus and newborn: what have we learned from animal models?
Lougaris et al. Autosomal recessive agammaglobulinemia: the third case of Igβ deficiency due to a novel non-sense mutation
Wu et al. Use of intravenous immunoglobulin in an A sian paediatric population over a 10‐year period
Kaleta et al. A retrospective description of a highly pathogenic avian influenza A virus (H7N1/Carduelis/Germany/72) in a free-living siskin (Carduelis spinus Linnaeus, 1758) and its accidental transmission to yellow canaries (Serinus canaria Linnaeus, 1758).
Hung et al. Anti-NMDAR encephalitis in association with herpes simplex virus and viral and bacterial zoonoses
Duan et al. Detection of invariant natural killer T cells in ejaculates from infertile patients with chronic inflammation of genital tract
Kaburaki et al. Anti-cardiolipin-β2-GPI complex antibodies in idiopathic thrombocytopenic purpura
Speck et al. A 31-year-old pregnant woman with angioedema.